Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah H, Geyer SM, Ganesan N, Chang T, Othman T, Shah GL, Nedved A, Durani U, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M, Armand P, Merryman RW

Open source

DOI: 10.1182/bloodadvances.2025018683
Published: 2026 Jun 9
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025018683,
  title = {Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.},
  author = {Falade AS and Redd R and Desai SH and Moskowitz AJ and Shah H and Geyer SM and Ganesan N and Chang T and Othman T and Shah GL and Nedved A and Durani U and Ng LS and Baron K and Ong SY and Yoon K and Ansell SM and Iyengar S and Micallef I and Stuver R and Herrera AF and Mei M and Armand P and Merryman RW},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025018683},
  url = {https://doi.org/10.1182/bloodadvances.2025018683}
}

RIS

TY  - JOUR
TI  - Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.
AU  - Falade AS
AU  - Redd R
AU  - Desai SH
AU  - Moskowitz AJ
AU  - Shah H
AU  - Geyer SM
AU  - Ganesan N
AU  - Chang T
AU  - Othman T
AU  - Shah GL
AU  - Nedved A
AU  - Durani U
AU  - Ng LS
AU  - Baron K
AU  - Ong SY
AU  - Yoon K
AU  - Ansell SM
AU  - Iyengar S
AU  - Micallef I
AU  - Stuver R
AU  - Herrera AF
AU  - Mei M
AU  - Armand P
AU  - Merryman RW
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025018683
UR  - https://doi.org/10.1182/bloodadvances.2025018683
ER  -

APA

AS, F., R, R., SH, D., AJ, M., H, S., SM, G., N, G., T, C., T, O., GL, S., A, N., U, D., LS, N., K, B., SY, O., K, Y., SM, A., S, I., I, M., R, S., AF, H., M, M., P, A., & RW, M. (2026). Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.. Blood advances. https://doi.org/10.1182/bloodadvances.2025018683

Source records

pubmed · retrieved 2026-09-27T01:36:20.550Z